Astellas Pharma Inc. ALPMY announced positive results from a phase IIIb randomized, double-blind study (BESIDE) on Myrbetriq as an add-on therapy to VESIcare in patients suffering from incontinent ...

MYRBETRIQ (mirabegron) 25mg and 50mg extended-release tablets by Astellas Astellas announced that the FDA has approved Myrbetriq (mirabegron) extended-release tablets for the treatment of overactive ...

NORTHBROOK, Ill., Oct. 22, 2012 -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that MYRBETRIQ™ (mirabegron) ...

MYRBETRIQ (mirabegron) 25mg and 50mg extended-release tablets by Astellas Astellas Pharma announced that Myrbetriq (mirabegron) extended-release tablets, indicated for the treatment of overactive ...

TOKYO, May 7, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved ...

NORTHBROOK, Ill., June 28, 2012 -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug ...

Astellas tapped independent agency Roska Healthcare as consumer agency-of-record for Astellas’ new overactive bladder pill, Myrbetriq (mirabegron). The agency announced the win in August, just over a ...

Myrbetriq, a drug, which offers new treatment option for overactive bladder (OAB), has been recently approved by the US Food and Drug Administration (FDA). Overactive bladder is a condition in which ...

TOKYO, June 29, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the submission of a supplemental New Drug Application (sNDA) to ...

Myrbetriq approved for overactive bladder Myrbetriq is indicated for adults with overactive to minimize symptoms of frequent urination and urinary incontinence. HealthDay News — The FDA has approved ...

Myrbetriq is a once daily oral beta-3 adrenergic agonist discovered and developed by Astellas. It has been studied extensively in more than 10,000 individuals over 10 years. [1] Myrbetriq offers a new ...